

# Study relationship between the human T lymphotropic virus infection and CML, AML Iraqi patients

Huda Salman Alagely

Department of medical and molecular Biotechnology / Biotechnology Research Center, Al-Nahrain University, Jadriya, Baghdad, Iraq.

Email :[Huda\\_alagely@yahoo.com](mailto:Huda_alagely@yahoo.com)

## Abstract

leukemia is linked with many disease because of the interruptions in patients immunity and its defect mechanisms against the foreign pathogens. Although the percentage of infected leukemia patients with HTLV is rare but its very important to diagnose this virus especially in leukemia patients. the severity and treatment of HTLV is depend on the viral load and infection stage of virus.

**Keyword:** HTLV, *pol* gene, leukemia, CML, AML,

## 1. Introduction

Human Lymphocyte T Virus (HLTV) is one of viruses which involve in human lymphocytes infection and other components of human blood causing lymphoma and leukemia [1,2}. this virus has two types, the first type called (HTLV-1) while the second type called (HTLV-2). The genetic material of virus is RNA which is single strand [3].

it was found that approximately 10 to 20 million of human are infected with human T lymphocyte virus all over the world [4,5]. It was found that 0.25 % to 2 % of the infected patients will get another disorder or disease in companied with HTLV such as neurologic disease and lymph disorders and others. even though the virus percentage found is rare [6], but it cause a serous problems when cause an infection for human especially the low immunity or

patient with auto immune diseases [7].

## 2. Material and Methods

One hundred and thirty leukemia patients were considered in this study 73 of these patients were CML, 57 were AML. Female samples were 80 while male samples 50. A sample of two ml blood was taken from every patient and DNA extraction were done using Gene aid DNA kit. Finally obtained DNA in a volume 50-100  $\mu$ l dissolved in TE buffer in Eppendorf tubes and these tubes were then kept at 20-C°.

### Detection of HTLV by *pol* gene specific primers

PCR used for determine *pol* gene to conform the identification of the HTLV, according to Cinna Gen Company the primers synthesized shown in (Table 1).

**Table (1): The sequence and concentration of forward and reverse primers of *pol* gene.[8]**

Primer type	Primers Sequence	Concentration in picomole	Product size
Pol forward	GTG GTG GAT TTG CCA TCG GGT TTT	30262.27	117 bp
Pol reverse	GTA CTT TAC TGA CAA ACC CGA CCT AC	35265.50	117bp

PCR reaction was conducted in master mix tube containing lypholyzied master mix table (2), with 20 $\mu$ l of reaction mixture containing, 1  $\mu$ l of forward primer, 1  $\mu$ l of reverse primer, template of DNA 5  $\mu$ l and 13  $\mu$ l of D.W. (Table 3).

**Table (2):-AccuPower® PCR Premix content.**

Reaction size	Component
1.5 $\mu$ M	MgCl <sub>2</sub>
250 $\mu$ M	dNTPs
1 U	Taq DNA polymerase
30 $\mu$ M	Kcl
10 $\mu$ M	Tris-HCL

**Table (3): - The mixture of conventional PCR working solution for detection of, *pol* gene to diagnose the HTLV infections**

Working solution	$\mu$ l
Water	13 $\mu$ l
Forward primer	1 $\mu$ l
Reverse primer	1 $\mu$ l
DNA	5 $\mu$ l
Final volume	20 $\mu$ l

Amplification was conducted using a master cyclor Eppendorf programmed with 45 cycle consist of three minutes Initial denaturation at 95°C, then five second for denaturation at 95°C, followed by annealing at 60°C for 30 second, then extension at 72°C for 30 second and finally Extension at 72°C for five minute[9] .

### RNA Extraction

The 130 blood samples of leukemia patients were taken. RNA of these samples was extracted by using RNA extraction kit (Geneaid extraction kit),

### Gene expression

It was used four set of primers in this study, two primers are forward and reverse and another two primer are reference gene . cDNA was obtained from RNA using Genaid specific kit.

The expression of this gene was then calculated.

### 3. Results and Discussion

This study involved 130 leukemia patients divided in to 73(56.15%) patients with CML and 57(43.84%) AML (fig 1).

The age of patients was ranged from 15-71 years, among 130 patients the number of male is 50 ( 38.46%) involved 18 ( 36%) AML and 32 (64%) CML ,while female number was 80 ( 61.53%) involved 39 ( 48.75%) AML and 41 (51.25%) CML (fig 2).




Figure 1: type of leukemia patients




Figure 2: the gender of groups

From this study the result of PCR reaction showed that it was only 2 of leukemia patients infected with HTLV in a prevalence 1.53% (fig 3). Both of infected patients with HTLV were chronic myeloid leukemia (CML)




Fig (3): The PCR products of pol gene that electrophoresis in agarose gel with concentration 2% and under voltage 5 volt to each 1 cm

M: 100 bp molecular ladder; well (1 and 3) positive  
423

product of 117 bp for pol gene, well (2,5) were negative , well 6 is negative control.




Fig (4): The RT-PCR of pol gene

Many studies conducted in the world to detect HTLV and its association with other disease . in India, Ramalingam and his colleagues found infections with HTLV in a percentage 9.3% in the patients with severe hematological malignancies, and detected 3 of 22 (13.6%) patients with leukemia were infected with HTLV [10].

The author Dourado et al. mention that occurrences and infection with HTLV increased with age from 1 to 89 years old, going from 0.3 to 1.1 and then to 1.1 and 8.4% among those age group are 0-15, 16-30, 31-50 and > 50 years old, respect [11]

Also, the infection may increase in the population as such the study of Dourado et. al who found that occurrences of Human T lymphocyte virus type 1 was increased in females in low education state.

### 4. Conclusions

From our above results reaction showed that leukemia patients infected with HTLV in a prevalence 1.53% the prevalence of infected patients' chronic myeloid leukemia (CML) with HTLV were much more the prevalence of AML.

### References

Arie Z., Jangu B., John P., Paul G., Barry S. (2004), Principles and Practice of Clinical Virology, 5th Edition, 767, 774, 768.

2- Pasqualetti P., Festuccia V., Acitelli P., Collacciani A., Giusti A., Casale R., (1997), Tobacco smoking and risk of haematological malignancies in adults: a case-control study, Br J Haematol. 1997 Jun;97(3):659-62.

Toru N., Shinichi K., Masako K., Toshimasa S., Naoki N., Kaori O., Atsushi H., Yoshikazu N., Ichiro T. (2009), Green Tea Consumption and Hematologic Malignancies in Japan, American Journal of Epidemiology, doi:10.1093/aje/kwp187.

Tuofu Zhu (2005) Human Retrovirus Protocols, Virology and Molecular Biology, V, 409, 114.

Arie Z., Jangu B., John P., Paul G., Barry S. (2004), Principles and Practice of Clinical Virology, 5th Edition, 767, 774, 768.

Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender A, de The G: Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet. 1985, 2: 407-410.

10.1016/S0140-6736(85)92734-5.

Mangano AM, Remesar M, del Pozo A, Sen L: Human T lymphotropic virus types I and II proviral sequences in Argentinian blood donors with indeterminate Western blot patterns. *J Med Virol.* 2004, 74: 323-327. 10.1002/jmv.20172.

Zou S, Dodd RY, Stramer SL, Strong DM, Tissue Safety Study Group: Probability of viremia with HBV, HCV, HIV, and HTLV among tissue donors in the United States. *N Engl J Med.* 2004, 351: 751-759. 10.1056/NEJMoa032510.

Manns A, Miley WJ, Wilks RJ, Morgan OS, Hanchard B, Wharfe G, Cranston B, Maloney E, Welles SL, Blattner WA, Waters D: Quantitative proviral DNA and antibody levels in the natural history of HTLV-I infection. *J Infect Dis.* 1999, 180: 1487-1493. 10.1086/315088.

Ramalingam S, Kannangai R, Prakash KJ, Ajithkumar K, Jacob M, George R, Pradeepkumar S, Daniel D, Dennison D, Babu PG. (2001), A pilot study of HTLV-I infection in high-risk individuals & their family members from India., *Indian J Med Res.* 2001 Jun;113:201-9.

Dourado I, Alcantara LCJ, Barreto ML, da Gloria TM, Galvão-Castro B. HTLV-I in the general population of Salvador, Brazil: a city with African ethnic and sociodemographic characteristics. *J Acquir Immune Defic Syndr.* 2003; 34:527-31.